ArticleLeukemia2014

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.

A Moros et al.PubMed ↗Publisher ↗

No numbers read from the abstract.